New Releases from NCBI BookshelfNintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 years (terminated appraisal).​Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 years (terminated appraisal).